Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03950076 · ClinicalTrials.gov registry record · Phase 4
EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)
A Phase 4 study of Atrial Fibrillation and Intracranial Hemorrhages, sponsored by Population Health Research Institute.
- Active
- Registry status
- Phase 4
- Development phase
- 948
- Enrollment target
- 20
- Study locations
NCT03950076: Active Phase 4 study of Atrial Fibrillation and Intracranial Hemorrhages, sponsored by Population Health Research Institute.
NCT03950076 is a Phase 4 study of Atrial Fibrillation and Intracranial Hemorrhages that is active but no longer recruiting, run by Population Health Research Institute. The registered enrollment target is 948 participants, below the 2,992-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (68% lower). The trial reports 20 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03950076, a Phase 4 study of Atrial Fibrillation and Intracranial Hemorrhages, is active but no longer recruiting, sponsored by Population Health Research Institute.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 4
- Development phase
- 948 participants
- Enrollment target
- 20
- Study locations
Study Summary
To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) or systemic embolism in high-risk atrial fibrillation (CHA2DS2-VASc ≥2) patients with previous intracranial hemorrhage.
Primary Outcome
Stroke (composite of ischemic, hemorrhagic and unspecified) or systemic embolism
Conditions Studied
Interventions
- DRUG Edoxaban
- OTHER Non-anticoagulant medical therapy
Study Locations (20)
Other
- Stat Research S.A. - Buenos Aires
- Hospital Italiano de Buenos Aires - Buenos Aires
- Fundación para la Lucha contra las Enfermedades Neurológicas de la Infancia (FLENI) - Buenos Aires
- Hospital Policial Churruca-Visca - Buenos Aires
- Centro Instituto Neurologico Salta - Salta
- Medical University of Innsbruck - Innsbruck
- Institut für Akutneurologie und Stroke Unit (IANS), Landeskrankenhaus Feldkirch - Rankweil
- Medical University of Vienna, Dept. of Neurology - Vienna
- Salzkammergutklinikum Vöcklabruck - Vöcklabruck
- Erasme Hospital - Brussels
Texas
- The University of Texas at Austin, Dell Medical School - Austin
- Texas Tech University Health Sciences Center at El Paso - El Paso
- Baylor St. Luke's Medical Center - Houston
Illinois
- Alexian Brothers Medical Center - Elk Grove Village
- Presence Care Transformation Corporation - Lisle
Pennsylvania
- The Hospital of the University of Pennsylvania - Philadelphia
- Allegheny General Hospital - Pittsburgh
Louisiana
- Tulane University Medical Center - New Orleans
New York
- New York Presbyterian - Queens - Queens
Washington
- MultiCare Institute for Research & Innovation - Tacoma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 948 participants |
| Start Date | 2019-09-20 |
| Est. Completion | 2026-05-13 |
| Phase | Phase 4 |
What the registry record for NCT03950076 still lists
NCT03950076 is an interventional study that assigns participants to a tested intervention. The registered 948 participants enrollment target is mid-sized for trials with a published cap, below the 2,992-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (68% lower).
The record links to 2 conditions, with Atrial Fibrillation appearing as the primary indexed condition, and to 2 interventions - of which Edoxaban is the first listed.
NCT03950076 names 20 study sites across 7 states, led by Other, Texas, Illinois.
Frequently Asked Questions
What is clinical trial NCT03950076 about?
NCT03950076 is a clinical study titled "EdoxabaN foR IntraCranial Hemorrhage Survivors With Atrial Fibrillation (ENRICH-AF)". To assess whether edoxaban (60/30 mg daily) compared to non-antithrombotic medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) or systemic embolism in high-risk atrial fibrillation (CHA2...
What is the current status of trial NCT03950076?
This trial is currently active not recruiting. It is a Phase 4 study. The enrollment target is 948 participants. The study started on 2019-09-20. Estimated completion is 2026-05-13.
What conditions does trial NCT03950076 study?
This clinical trial studies the following conditions: Atrial Fibrillation, Intracranial Hemorrhages.
What interventions are being tested in trial NCT03950076?
The interventions under investigation include: Edoxaban (DRUG), Non-anticoagulant medical therapy (OTHER).
Who is sponsoring clinical trial NCT03950076?
This trial is sponsored by Population Health Research Institute, which has 21 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03950076 being conducted?
This trial has 20 study locations across Illinois, Louisiana, New York, Pennsylvania, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Atrial Fibrillation
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03950076's enrollment target sits among peer trials
948 42nd of 202 higher than 161 of 202 other Atrial Fibrillation trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Treatment Of Atrial Fibrillation In Preserved Cardiac Function Heart Failure
RECRUITING · Phase 4
-
Pharmacogenetic Study of Antiarrhythmic Drugs for Atrial Fibrillation
RECRUITING · Phase 4
-
Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress
RECRUITING · Phase 4
-
Ondansetron for the Management of Atrial Fibrillation
RECRUITING · Phase 4
-
Therapeutic Initial Heparin Dosing for Patients With Clots or Certain Heart Conditions Admitted to the Hospital
ACTIVE NOT RECRUITING · Phase 4
-
Targeting Risk Interventions and Metformin for Atrial Fibrillation (TRIM-AF)
ACTIVE NOT RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04895709 · 949 participants · Phase 1
A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
- NCT06087224 · 947 participants · NA
The TELENEO Trial: A Multicenter Trial of Telemedicine for Advanced Neonatal Resuscitations in Community Hospitals
- NCT03784924 · 950 participants
EDRN Prostate MRI Biomarker Study
- NCT04180930 · 950 participants
An Evaluation of Two PTSD Assessments in an Active Duty and Military Veteran Sample
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI